Log in

NASDAQ:ATXIAvenue Therapeutics Stock Price, Forecast & News

$10.47
-0.03 (-0.29 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.34
Now: $10.47
$10.65
50-Day Range
$9.72
MA: $10.77
$11.47
52-Week Range
$4.96
Now: $10.47
$11.83
Volume83,905 shs
Average Volume86,372 shs
Market Capitalization$174.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.2
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Read More
Avenue Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.94 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATXI
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.41 per share

Profitability

Net Income$-25,910,000.00

Miscellaneous

Employees6
Market Cap$174.64 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

How has Avenue Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATXI shares have increased by 40.7% and is now trading at $10.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avenue Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avenue Therapeutics.

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Avenue Therapeutics.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics Inc (NASDAQ:ATXI) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09. View Avenue Therapeutics' earnings history.

What price target have analysts set for ATXI?

1 Wall Street analysts have issued twelve-month price targets for Avenue Therapeutics' stock. Their forecasts range from $13.00 to $13.00. On average, they expect Avenue Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 24.2% from the stock's current price. View analysts' price targets for Avenue Therapeutics.

Has Avenue Therapeutics been receiving favorable news coverage?

News headlines about ATXI stock have trended negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avenue Therapeutics earned a news impact score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View the latest news about Avenue Therapeutics.

Who are some of Avenue Therapeutics' key competitors?

What other stocks do shareholders of Avenue Therapeutics own?

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 64)
  • Dr. Lucy Lu, Pres, CEO & Director (Age 44)
  • Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 35)
  • Dr. Scott A. Reines, Interim Chief Medical Officer (Age 72)

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $10.47.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $174.64 million. The company earns $-25,910,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Avenue Therapeutics employs 6 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is www.avenuetx.com.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.